default author photo

Pascal Brabant

Immune Biosolutions Inc

SCHOLARLY PAPERS

1

DOWNLOADS

180

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Safety and Efficacy of Inhaled IBIO123 for Severe COVID-19: A Randomised, Double-Blind, Dose-Ascending, Placebo-Controlled, Phase 1/2 Trial

Number of pages: 35 Posted: 06 Oct 2023
Immune Biosolutions Inc, Immune Biosolutions Inc, Immune Biosolutions Inc, Immune Biosolutions Inc, Immune Biosolutions Inc, Immune Biosolutions Inc, Immune Biosolutions Inc, Immune Biosolutions Inc, Immune Biosolutions Inc, Centre de Recherche du CHUM, Immune Biosolutions Inc, Ryexo Clinical Research and Independent
Downloads 180 (422,345)

Abstract:

Loading...

COVID-19, monoclonal antibody, inhalation, therapy